Vanessa del Pozo

Vanessa del Pozo

Auto-generated profile, based on publicly available information

Vanessa del Pozo

UT Health Science Center at San Antonio 1 Greehey Children’s Cancer Research Institute San Antonio, Texas

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EFEdward Favours
Edward Favours
HTHaiying Tang
Haiying Tang
PWPeyton Wong
Peyton Wong
SGSamuel Ghilu
Samuel Ghilu
VPVanessa del Pozo
Vanessa del Pozo
RKRaushan Kurmasheva
Raushan Kurmasheva
Purpose: Vobramitamab duocarmazine (vobra duo) is a duocarmycin-based, humanized antibody–drug conjugate (ADC) targeting B7-H3, with a drug-to-antibody ratio of ∼2.7. Vobra duo has demonstrated robust antitumor activity in multiple adult cancer models, along with favorable pharmacokinetic and safety profiles in cynomolgus monkeys. Early results from phase I/II clinical trials (NCT03729596) have shown manageable toxicity and promising objective responses in patients with metastatic castration-resistant prostate cancer. Given the high expression of B7-H3 in pediatric solid tumors, this target is emerging as a compelling therapeutic opportunity in pediatric oncology. Experimental Design: Antitumor activity of vobra duo was evaluated in pediatric solid tumor xenograft models, including Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, osteosarcoma, malignant rhabdoid tumor, hepatoblastoma, and Wilms tumor. Tumor-bearing mice received a single intraperitoneal dose of vobra duo (6 mg/kg) or a matched control ADC (SYD988, anti-CD20 ADC with an identical linker and payload). Tumor progression was defined as a fourfold increase in tumor volume. Event-free survival was analyzed using Kaplan–Meier methods, and objective responses were categorized as partial, complete, or maintained complete response. Results: Vobra duo induced objective responses across multiple tumor types, whereas the control ADC showed limited activity. No clear association was observed between B7-H3 protein expression and therapeutic response. Conclusions: These findings demonstrate the broad preclinical efficacy of vobra duo in pediatric solid tumors and support further clinical investigation of B7-H3–targeted therapies in children.

17 July 2026
Verified
Other
Open access
EFEdward Favours
Edward Favours
HTHaiying Tang
Haiying Tang
PWPeyton Wong
Peyton Wong
SGSamuel Ghilu
Samuel Ghilu
VPVanessa del Pozo
Vanessa del Pozo
RKRaushan Kurmasheva
Raushan Kurmasheva
Plots of event-free-survival (EFS) and relative tumor volume (RTV) changes over time for osteosarcoma models. Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1. Bold lines on RTV plots represent group median tumor volume changes.

17 July 2026
Verified
Other
Open access
EFEdward Favours
Edward Favours
HTHaiying Tang
Haiying Tang
PWPeyton Wong
Peyton Wong
SGSamuel Ghilu
Samuel Ghilu
VPVanessa del Pozo
Vanessa del Pozo
RKRaushan Kurmasheva
Raushan Kurmasheva
CD276 gene expression from pedcBioportal public databases (to support Figure 4B).

17 July 2026
Verified
Other
Open access
EFEdward Favours
Edward Favours
HTHaiying Tang
Haiying Tang
PWPeyton Wong
Peyton Wong
SGSamuel Ghilu
Samuel Ghilu
VPVanessa del Pozo
Vanessa del Pozo
RKRaushan Kurmasheva
Raushan Kurmasheva
Efficacy testing summary results for RMS models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C= SYD988: 6 mg/kg, IP, Day 0 × 1.

17 July 2026
Verified
Other
Open access
EFEdward Favours
Edward Favours
HTHaiying Tang
Haiying Tang
PWPeyton Wong
Peyton Wong
SGSamuel Ghilu
Samuel Ghilu
VPVanessa del Pozo
Vanessa del Pozo
RKRaushan Kurmasheva
Raushan Kurmasheva
Plots of event-free-survival (EFS) and relative tumor volume (RTV) changes over time for Wilms tumor models. Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1. Bold lines on RTV plots represent group median tumor volume changes.

17 July 2026
Verified
Other
Open access
EFEdward Favours
Edward Favours
HTHaiying Tang
Haiying Tang
PWPeyton Wong
Peyton Wong
SGSamuel Ghilu
Samuel Ghilu
VPVanessa del Pozo
Vanessa del Pozo
RKRaushan Kurmasheva
Raushan Kurmasheva
Plots of event-free-survival (EFS) and relative tumor volume (RTV) changes over time for neuroblastoma models. Treatment groups: A = control (dark gray), B = vobra duo (blue): 6 mg/kg, IP, Day 0 × 1, C=SYD988 (light gray): 6 mg/kg, IP, Day 0 × 1. Bold lines on RTV plots represent group median tumor volume changes.